Actively Recruiting
Testing Doses of BI 3968621 Alone or With Ezabenlimab in Adults With Advanced Solid Tumors to Assess Safety and Tumor Response
Led by Boehringer Ingelheim · Updated on 2026-10-28
90
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying adults with advanced solid tumors that cannot be removed by surgery or have spread to other parts of the body. The trial aims to identify the highest and most suitable dose of the drug BI 3968621, given alone or with ezabenlimab, that patients can tolerate. This is a first-in-human phase 1 study assessing safety, tolerability, and preliminary anti-tumor activity of these medicines in people with advanced cancer. The study has three parts Part A, Part A2, and Part B. Participants receive BI 3968621 alone or in combination with ezabenlimab depending on the study part. BI 3968621 is taken daily as tablets, while ezabenlimab is given as an infusion into a vein every three weeks. Part A finds the suitable dose of BI 3968621 alone, Part A2 evaluates tumor response in kidney cancer at specific doses, and Part B assesses tolerability of the combination treatment. Participants may receive treatment for up to two years if they benefit and tolerate it. During the study, participants visit the study site regularly according to their response and tolerance. Researchers monitor severe health problems occurring within three weeks after the first treatment. They also assess participants overall health, record side effects, take blood samples, and evaluate how the cancer responds to the treatments. The main outcome measures include dose-limiting toxicities during the first treatment cycle and objective tumor response up to two years.
CONDITIONS
Brief Title
A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced Cancer
Research Team
B
Boehringer Ingelheim
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here